Why current breast pathology practices must be evaluated. A Susan G. Komen for the Cure white paper: June 2006.
about
Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.Understanding diagnostic variability in breast pathology: lessons learned from an expert consensus review panel.Why the term 'low-grade ductal carcinoma in situ' should be changed to 'borderline breast disease': diagnostic and clinical implications.Histological features associated with diagnostic agreement in atypical ductal hyperplasia of the breast: illustrative cases from the B-Path study.Minimizing Errors in Breast Pathology: A Call for Action.
P2860
Why current breast pathology practices must be evaluated. A Susan G. Komen for the Cure white paper: June 2006.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Why current breast pathology p ...... e Cure white paper: June 2006.
@en
type
label
Why current breast pathology p ...... e Cure white paper: June 2006.
@en
prefLabel
Why current breast pathology p ...... e Cure white paper: June 2006.
@en
P2093
P2860
P1433
P1476
Why current breast pathology p ...... e Cure white paper: June 2006.
@en
P2093
Cheryl Perkins
Diane Balma
Members of the Consensus Group
Rebecca Garcia
Susan G. Komen for the Cure
P2860
P304
P356
10.1111/J.1524-4741.2007.00463.X
P577
2007-09-01T00:00:00Z